Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine concizumab (brand name: Alhemo) to prevent or reduce the frequency of bleeding episodes (prophylaxis) in people aged 12 years and older with haemophilia A or B with inhibitors.

Haemophilia is a rare, inherited condition that affects the way blood clots. People with haemophilia A or B are at higher risk of bleeding because they lack proteins that help the blood clot (clotting factor VIII for haemophilia A and clotting factor IX for haemophilia B).

The active substance, concizumab, which acts independently of factor VIII and factor IX, works by blocking a natural protein that prevents blood from clotting (known as tissue factor pathway inhibitor). By inhibiting this protein, concizumab increases Factor